ERVEBO

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug ERVEBO contains one active pharmaceutical ingredient (API):

1
UNII P7ZRG1LJ3A - EBOLA VIRUS/H. SAPIENS-TC/COD/1995/KIKWIT-9510622 ENVELOPE GLYCOPROTEIN GENE (VIRAL NEGATIVE STRAND)
 

Ebola vaccine consists of a live, attenuated recombinant vesicular stomatitis virus-based vector expressing the envelope glycoprotein gene of Zaire Ebola virus (rVSV∆G-ZEBOV-GP). Immunisation of subjects with the vaccine results in an immune response and protection from Zaire Ebola Virus Disease (EVD).

 
Read more about Ebola vaccine

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 ERVEBO Solution for injection MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J07BX02 J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1806713
FR Base de données publique des médicaments 62614126
IT Agenzia del Farmaco 048364018
LT Valstybinė vaistų kontrolės tarnyba 1088943
PL Rejestru Produktów Leczniczych 100424330

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.